Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
SPOP mutations increase PARP inhibitor sensitivity via CK2/PIAS1/SPOP axis in prostate cancer
Hui Zhang, Lili Kong, Jinhui Li, Zhihan Liu, Yiting Zhao, Xiuyi Lv, Liangpei Wu, Lin Chai, Hongjie You, Jiabei Jin, Xinyi Cao, Zhong Zheng, Yadong Liu, Zejun Yan, Xiaofeng Jin
Hui Zhang, Lili Kong, Jinhui Li, Zhihan Liu, Yiting Zhao, Xiuyi Lv, Liangpei Wu, Lin Chai, Hongjie You, Jiabei Jin, Xinyi Cao, Zhong Zheng, Yadong Liu, Zejun Yan, Xiaofeng Jin
View: Text | PDF
Research Article Cell biology Genetics Oncology

SPOP mutations increase PARP inhibitor sensitivity via CK2/PIAS1/SPOP axis in prostate cancer

  • Text
  • PDF
Abstract

It is well documented that impaired DNA damage repair (DDR) induces genomic instability that can efficiently increase the sensitivity of prostate cancer (PCa) cells to PARP inhibitors; however, the underlying mechanism remains elusive. Here, we found profound genomic instability in PCa cells with SPOP gene mutations and confirmed the sensitivity of SPOP-mutated PCa cells to olaparib-induced apoptosis. Mechanistically, we identified olaparib-induced CK2-mediated phosphorylation of PIAS1-S468, which in turn mediated SUMOylation of SPOP, thus promoting its E3 ligase activity in the DDR. Moreover, an abnormal CK2/PIAS1/SPOP axis due to SPOP mutations or defects in CK2-mediated phosphorylation of PIAS1, as well as SPOP inhibitor treatment, led to impaired DDR, thus increasing olaparib-induced apoptosis of PCa cells and enhancing olaparib sensitivity in animal models and patient-derived organoids. This suggested that disruption of the CK2/PIAS1/SPOP signaling axis could serve as an indicator for targeted therapy of PCa using a PARP inhibitor.

Authors

Hui Zhang, Lili Kong, Jinhui Li, Zhihan Liu, Yiting Zhao, Xiuyi Lv, Liangpei Wu, Lin Chai, Hongjie You, Jiabei Jin, Xinyi Cao, Zhong Zheng, Yadong Liu, Zejun Yan, Xiaofeng Jin

×

Figure 3

PIAS1 mediates SUMOylation of SPOP upon DNA damage.

Options: View larger image (or click on image) Download as PowerPoint
PIAS1 mediates SUMOylation of SPOP upon DNA damage.
(A) In vivo SUMOylat...
(A) In vivo SUMOylation assays showing the PIAS1-mediated SUMOylation of SPOP using lysates from HEK-293T cells transfected with FLAG-SPOP and increased dosage of Myc-PIAS1 plasmids, staining with anti-FLAG, anti-SUMO1, anti-SUMO2/3, anti-Myc, and anti-actin antibodies. (B) In vitro SUMOylation assays using reconstituted His-PIAS1, E1 and E2 enzymes, ATP, SUMO1, and GST-SPOP to show the PIAS1-mediated SUMOylation of SPOP. (C) In vivo SUMOylation assays showing the PIAS1-mediated enhanced SUMOylation of SPOP under olaparib (10 μM) treatment using lysates from HEK-293T cells transfected with FLAG-SPOP and Myc-PIAS1 plasmids, staining with anti-FLAG and anti-Myc bodies. (D) Mass spectrometry analysis showing potential SUMOylation site of SPOP. (E) In vivo SUMOylation assays showing the PIAS1-mediated SUMOylation of SPOP under olaparib (10 μM) treatment using lysates from HEK-293T cells transfected with FLAG-SPOP-WT or FLAG-SPOP-MUT and Myc-PIAS1 plasmids, staining with anti-FLAG, anti-Myc, and anti-SUMO1 antibodies.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts